LATEST

Diet and lifestyle factors may trigger psoriasisEnvironmental and lifestyle factors, such as certain foods and infections, may trigger onset of psoriasis and account for approximately 30% of the risk of the condition in people with a genetic preposition, research presented in London shows.
Isotretinoin may ameliorate depression symptomsPooled meta-analysis does not support association between isotretinoin treatment for acne and worsening of depression.
Less isotretinoin monitoring?The lack of serious laboratory abnormalities in patients on isotretinoin suggests that reduced monitoring may suffice.
Daylight photodynamic therapy as effective as conventional therapy for actinic keratosis
Daylight photodynamic therapy as effective as conventional therapy for actinic keratosisConventional photodynamic therapy is highly effective for actinic keratoses, but daylight photodynamic therapy proves to be just as effective and more tolerable, a study shows.
Chest actinic keratoses responds to low-level ingenol mebutate topicalA lower level concentration of ingenol mebutate gel for the chest significantly reduces actinic keratosis lesion counts without severe side effects, a study shows.
6 puzzling cases to crackWe know you love a good diagnostic challenge. Can you solve these 6 cases that we've featured over the past year?
AD drug development driven by symptom and disease controlDrug development for established atopic dermatitis focuses on both managing flares and long-term disease control.
False moisturizer claims may worsen skin conditionsMost moisturizes contain ingredients that are not advertised and could potentially harm some patients, study shows.
Restarting TNFi treatment after a break proves beneficial in psoriasisSwitching from adalimumab to etanercept or vice versa after interruption can improve treatment response, data presented in London suggests.
Hard-to-treat psoriasis cases respond to secukinumabSecukinumab has been shown to be effective for the treatment of moderate-to-severe plaque psoriasis in hard-to-treat patients who failed anti-TNFa treatment, researchers report in London.

Poll

View Results